Product Name :
PD0166285 dihydrochloride
Description:
PD0166285 dihydrochloride, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC50 values of 24 and 72 nM, respectively. PD0166285 dihydrochloride exhibits an IC50 of 3.433 μM for Chk1.
CAS:
212391-63-4
Molecular Weight:
585.35
Formula:
C26H29Cl4N5O2
Chemical Name:
6-(2, 6-dichlorophenyl)-2-((4-(2-(diethylamino)ethoxy)phenyl)amino)-8-methylpyrido[2, 3-d]pyrimidin-7(8H)-one dihydrochloride
Smiles :
Cl.Cl.CN1C(=O)C(=CC2=CN=C(NC3C=CC(=CC=3)OCCN(CC)CC)N=C12)C1C(Cl)=CC=CC=1Cl
InChiKey:
NADLBPWBFGTESN-UHFFFAOYSA-N
InChi :
InChI=1S/C26H27Cl2N5O2.2ClH/c1-4-33(5-2)13-14-35-19-11-9-18(10-12-19)30-26-29-16-17-15-20(25(34)32(3)24(17)31-26)23-21(27)7-6-8-22(23)28;;/h6-12,15-16H,4-5,13-14H2,1-3H3,(H,29,30,31);2*1H
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
PD0166285 dihydrochloride, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC50 values of 24 and 72 nM, respectively. PD0166285 dihydrochloride exhibits an IC50 of 3.433 μM for Chk1.|Product information|CAS Number: 212391-63-4|Molecular Weight: 585.35|Formula: C26H29Cl4N5O2|Chemical Name: 6-(2, 6-dichlorophenyl)-2-((4-(2-(diethylamino)ethoxy)phenyl)amino)-8-methylpyrido[2, 3-d]pyrimidin-7(8H)-one dihydrochloride|Smiles: Cl.Cl.CN1C(=O)C(=CC2=CN=C(NC3C=CC(=CC=3)OCCN(CC)CC)N=C12)C1C(Cl)=CC=CC=1Cl|InChiKey: NADLBPWBFGTESN-UHFFFAOYSA-N|InChi: InChI=1S/C26H27Cl2N5O2.{{Dostarlimab} site|{Dostarlimab} Immunology/Inflammation|{Dostarlimab} Purity & Documentation|{Dostarlimab} Description|{Dostarlimab} manufacturer|{Dostarlimab} Autophagy} 2ClH/c1-4-33(5-2)13-14-35-19-11-9-18(10-12-19)30-26-29-16-17-15-20(25(34)32(3)24(17)31-26)23-21(27)7-6-8-22(23)28;;/h6-12,15-16H,4-5,13-14H2,1-3H3,(H,29,30,31);2*1H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Cyproheptadine} MedChemExpress|{Cyproheptadine} Apoptosis|{Cyproheptadine} Biological Activity|{Cyproheptadine} Data Sheet|{Cyproheptadine} custom synthesis|{Cyproheptadine} Epigenetic Reader Domain} |Shelf Life: ≥12 months if stored properly.PMID:25955218 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PD0166285 (0.5 μM) dramatically inhibits irradiation-induced Cdc2 phosphorylation at the Tyr-15 and Thr-14 in seven of seven cancer cell lines. PD0166285 sensitizes radiation-induced cell killing in p53 mutant HT29 cells and in the E6-transfected, p53-null ovarian cancer cell line PA-1 but to a lesser extent in p53 wild-type PA-1 cells. PD0166285 abrogates irradiation-induced G2 arrest and significantly increases mitotic cell populations. PD0166285 acts as a radiosensitizer to sensitize cells to radiation-induced cell death with a sensitivity enhancement ratio of 1.23.|Products are for research use only. Not for human use.|